Clinical Trial Update: MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001) [Phase 1]

View source ↗

Summary

A Phase 1 study of MK0457, an Aurora kinase inhibitor, in patients with advanced colorectal cancer and other advanced solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Solid Tumors

Drugs mentioned

• MK0457 (VX-680)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Cancer, Advanced Solid Tumors | Phase 1 | Status: TERMINATED